[{"orgOrder":0,"company":"Groupe d'Etude sur le Risque d'Exposition","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Groupe d'Etude sur le Risque d'Exposition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Groupe d'Etude sur le Risque d'Exposition \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Groupe d'Etude sur le Risque d'Exposition \/ Gilead Sciences"},{"orgOrder":0,"company":"IRCCS San Raffaele","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"IRCCS San Raffaele","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IRCCS San Raffaele \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"IRCCS San Raffaele \/ Gilead Sciences"},{"orgOrder":0,"company":"Fundacion SEIMC-GESIDA","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Fundacion SEIMC-GESIDA","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fundacion SEIMC-GESIDA \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Fundacion SEIMC-GESIDA \/ Merck & Co"},{"orgOrder":0,"company":"Genuine Research Center, Egypt","sponsor":"Apex Pharmaceuticals, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"EGYPT","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Genuine Research Center, Egypt","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genuine Research Center, Egypt \/ Apex Pharmaceuticals, Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Genuine Research Center, Egypt \/ Apex Pharmaceuticals, Inc."},{"orgOrder":0,"company":"University of California, Los Angeles","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"University of California, Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of California, Los Angeles \/ Gilead Sciences","highestDevelopmentStatusID":"7","companyTruncated":"University of California, Los Angeles \/ Gilead Sciences"},{"orgOrder":0,"company":"Saskatchewan Health Authority \u2013 Regina Area","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Saskatchewan Health Authority \u2013 Regina Area","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saskatchewan Health Authority \u2013 Regina Area \/ Gilead Sciences","highestDevelopmentStatusID":"11","companyTruncated":"Saskatchewan Health Authority \u2013 Regina Area \/ Gilead Sciences"},{"orgOrder":0,"company":"Ottawa Hospital Research Institute","sponsor":"Gilead Sciences | CIHR Canadian HIV Trials Network","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ottawa Hospital Research Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ottawa Hospital Research Institute \/ Gilead Sciences | CIHR Canadian HIV Trials Network","highestDevelopmentStatusID":"10","companyTruncated":"Ottawa Hospital Research Institute \/ Gilead Sciences | CIHR Canadian HIV Trials Network"},{"orgOrder":0,"company":"Henry M. Jackson Foundation","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Henry M. Jackson Foundation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Henry M. Jackson Foundation \/ Gilead Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Henry M. Jackson Foundation \/ Gilead Sciences"},{"orgOrder":0,"company":"University of Washington","sponsor":"Clinique des Maladies Infectieuses Ibrahima DIOP Mar\/CRCF, Centre Hospitalier Universitaire de Fann | Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Washington \/ Clinique des Maladies Infectieuses Ibrahima DIOP Mar\/CRCF, Centre Hospitalier Universitaire de Fann | Gilead Sciences","highestDevelopmentStatusID":"11","companyTruncated":"University of Washington \/ Clinique des Maladies Infectieuses Ibrahima DIOP Mar\/CRCF, Centre Hospitalier Universitaire de Fann | Gilead Sciences"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Brigham and Women's Hospital | Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Brigham and Women's Hospital | Gilead Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Massachusetts General Hospital \/ Brigham and Women's Hospital | Gilead Sciences"},{"orgOrder":0,"company":"Haitian Group for Study of Kaposi's Sarcoma","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HAITI","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Haitian Group for Study of Kaposi's Sarcoma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haitian Group for Study of Kaposi's Sarcoma \/ Gilead Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Haitian Group for Study of Kaposi's Sarcoma \/ Gilead Sciences"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Kenneth H. Mayer, MD","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Kenneth H. Mayer, MD","highestDevelopmentStatusID":"11","companyTruncated":"Gilead Sciences \/ Kenneth H. Mayer, MD"}]
Find Clinical Drug Pipeline Developments & Deals for Elvitegravir
Details :
Elvitegravir is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of HIV Infections.
Details :
Elvitegravir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of HIV Infections.
Details :
Elvitegravir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of HIV Infections.
Details :
Elvitegravir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of HIV Infections.
Details :
Elvitegravir is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of HIV Infections.
Details :
Elvitegravir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of HIV Infections.
Details :
Elvitegravir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of HIV Infections.
Details :
Elvitegravir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of HIV Infections.
Details :
Elvitegravir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of HIV Infections.
Details :
Elvitegravir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of HIV Infections.
Reset All
